WARNING: Combined Medical Device ADVISORY And FDA Regulatory Framework Analysis
Nyenta.com/10343430

NEW YORK - Nyenta -- PUBLIC ADVISORY — DIRECTED TO: Medical device recipients, healthcare providers, hospital systems, surgical centers, implant registries, device manufacturers, regulatory authorities, and all parties with standing in the conformity assessment chain governing medical device safety in the United States and internationally.

WARNING: "MEDICAL DEVICE RECIPIENTS

Between 2018 and the present date, medical devices — including heart valves, hip and knee implants, surgical instruments, implantable cardiac devices, spinal fusion hardware, vascular stents, pacemaker components, and life-support apparatus — may have been manufactured, certified, and approved under an accreditation environment documented as member. The compromise originates at the apex of the accreditation architecture itself.

The American National Accreditation Board (ANAB) falsely identified itself as an "underwriter" for the International Accreditation Forum (IAF, Inc., Delaware) in U.S. Department of State Contract No. 19AQMM18R0131 (2018). No such role exists within the governance structures of the IAF or ILAC (Australia). No IAF bylaw, resolution, or governance framework authorizes an "underwriter" function. This misrepresentation was also published on a private laboratory website and in a technical journal. IAF and ILAC merged in January 2026 to form GLOBAC. Reference GUBERMAN-ANOMALY-DISCOVERY https://guberman-quality.com/wp content/uploads/2026/03/GUBERMAN-ANOMALY-FEBRUARY-2026.docx.pdf

A second federal contract, No. 15F06725C0000139 (2025), documents ANAB's continued involvement in federal accreditation, establishing that federal reliance persisted through 2025 and into 2026.

COMPROMISED OVERSIGHT ENVIRONMENT (2018–2026)

Devices manufactured during this period may have been produced under accreditation conditions now in question, including: ISO 13485 certifications issued by ANAB-accredited registrars; MedAccred special-process approvals governing heat treating, welding, chemical processing, coatings, and NDT; supply-chain validations reliant upon ANAB; and quality-system surveillance tied to ANAB's status. PRI, MedAccred, and NADCAP all sit under ANAB's umbrella. When the top of the chain is compromised, everything beneath it is structurally contaminated. Systemic Certification Breakdown

More on Nyenta.com

• STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry
• Nyasia Chane'l Celebrates 5 Years of Clubhouse No. 7 With Deluxe Edition
• West Virginia Leaders Announce Support for Election Integrity Network's Model Election Laws Handbook
• Venture Philanthropy Blueprint by Alain Leroy Published
• CCHR Condemns Behavioral Treatment After FDA's Missed Deadline to Ban Shock Device

FDA REGULATORY FRAMEWORK IMPLICATED

The following federal regulations are directly violated or undermined by the compromised accreditation environment:

21 CFR Part 820 (Quality System Regulation): Establishes cGMP requirements for all medical devices. Manufacturers demonstrate compliance through ISO 13485 certification issued by ANAB-accredited bodies. When the accreditation body committed documented fraud in Contract No. 19AQMM18R0131, the entire quality system certification is rendered structurally invalid.

21 CFR §820.10 (Design Controls Scope): Requires quality systems conforming to recognized standards. When ISO 13485 is certified by a fraudulent accreditation authority, the chain of conformity is broken at its origin.

21 CFR §820.180 (Records): Requires all quality system records to be complete, accurate, and truthful. Records incorporating ANAB's fraudulent accreditation certificate are structurally tainted — legible and retrievable, but not truthful in foundational premise.

21 CFR §820.70 (Production and Process Controls): Requires validated production processes under a valid quality system. When the accreditation foundation is fraudulent, process validation is structurally deficient.

ISO 13485 (Medical Devices QMS): The international standard harmonized with Part 820. Every ISO 13485 certificate issued under ANAB accreditation during 2018–Present is structurally compromised. The deficiency propagates: from ANAB to certification body, to manufacturer's certificate, to every device under its scope.

21 CFR Part 803 (Medical Device Reporting): Requires reporting of conditions that could contribute to adverse events. A compromised accreditation environment constitutes an institutional malfunction — a reportable condition under Part 803.

21 CFR Part 806 (Corrections and Removals): Requires reporting to remedy FD&C Act violations. When Part 820 compliance rests on ISO 13485 certification under fraudulent accreditation, a violation may exist independent of any physical device defect.

21 CFR Part 821 (Device Tracking): Establishes tracking for permanently implantable, life-sustaining, and life-supporting devices. Tracking is the operational infrastructure for identifying affected devices — heart valves, pacemakers, implants, vascular grafts, life-support equipment — manufactured under the compromised umbrella.

DECEMBER 2018 ANSI TAKEOVER OF ANAB

On December 28, 2018, ANSI completed acquisition of full ownership of ANAB from ASQ, consolidating standards-making and accreditation authority under one corporate parent — in the same year as Contract No. 19AQMM18R0131. The entity that defines requirements now controls the entity that determines who may certify compliance. ASQ's removal eliminated the last independent check on ANSI's influence.

More on Nyenta.com

• VINCE Magazine Launches New Digital Hub, Inviting Fitness and Wellness Professionals to Collaborate
• Brilliant Minds to Gather in Fort Worth for National Mensa Event
• UK Financial Ltd Completes One Of The Most Extensive CoinMarketCap Supply Verification Packages For Maya Preferred PRA (MPRA)
• Data Tiles Strengthens U.S. Presence with Chief Revenue Officer John Goode
• Love All: Liberty Open 2026 Serves Pride with USTA Partnership

THE FDA AS BOTH MEMBER AND CUSTOMER

The FDA sits as a member on the ANSI-ANAB board and participates in governance, committee work, and accreditation policy. The FDA is simultaneously a paying customer, relying on ANAB-accredited bodies to verify compliance with ISO 13485 and 21 CFR Part 820. The FDA authored and enforces the very regulations — Parts 820, 803, 806, and 821 — violated at the apex of the certification chain. The FDA was positioned to know, or should have known, that its accreditation body committed material fraud in a federal contract. The DOJ is also both a board member and customer.

FDA Recognizes First Accreditation Body Under Accredited Third-Party Certification Program and Launches Voluntary Qualified Importer Program https://www.khlaw.com/insights/fda-recognizes-first-accreditation-body-under-accredited-third-party-certification-program

ANSI National Accreditation Board (ANAB) Accredits Auditing Operation Services to Certify Foreign Food Supplies under U.S. FDA-FSMA Program https://www.prnewswire.com/news-releases/ansi-national-accreditation-board-anab-accredits-auditing-operation-services-to-certify-foreign-food-supplies-under-us-fda-fsma-program-301269988.html

Systemic Certification Breakdown: FAA & FDA Standards Compromised by ANAB's Misrepresentation from 2018–2026 https://www.prlog.org/13135381-systemic-certification-breakdown-faa-fda-standards-compromised-by-anabs-misrepresentation-from-20182026.html

CONCLUSION

The accreditation environment governing U.S. medical device manufacturing has been documented as structurally compromised from 2018 to Present. Two federal contracts — No. 19AQMM18R0131 (2018) and No. 15F06725C0000139 (2025) — define the origin and duration of the fraud. Every device manufactured under this umbrella carries the structural deficiency of the oversight system that approved it. The deficiency is cumulative, irreversible, and not remediable through inspection, testing, or administrative waiver. No FDA waiver can undo fraudulent oversight. The conditions of approval are historical facts.

"The FDA's own rules say that if the quality system is based on fraudulent accreditation the device is legally 'adulterated.' Since the FDA now builds that system on ISO 13485 and Part 820/QMSR, any fraudulent certification or accreditation in that chain means the implants and devices made under it are not legally valid products. They're built in a system the law itself would call adulterated."

"All who rise while burying the truth will one day be buried by it."
-Anonymous (proverbial wisdom)